---
title: "Glycoprotein IIb/IIIa Agents in Acute Ischemic Stroke: A Niche in the Making?"
description: "Variations in thrombus composition significantly influence the efficacy of conventional thrombolytic therapies in acute ischemic stroke. Emerging treatments, designed to target distinct components of the thrombus, are currently under evaluation and o..."
date: "2026-03-01"
category: "investigacion"
pubmedId: "41730038"
author: "Vignan Yogendrakumar, Ronda Lun, Bruce C V Campbell et al."
tags: ["abciximab", "clinical trial", "eptifibatide", "glycoproteins", "ischemic stroke"]
---

## Resumen

Variations in thrombus composition significantly influence the efficacy of conventional thrombolytic therapies in acute ischemic stroke. Emerging treatments, designed to target distinct components of the thrombus, are currently under evaluation and offer renewed hope for enhancing clot dissolution and improving clinical outcomes. This review will examine the current evidence surrounding glycoprotein IIb/IIIa inhibitors in the treatment of acute ischemic stroke, drawing on the latest randomised-controlled trials, identifying promising therapeutic candidates and evaluating the clinical contexts in which these agents are most likely to be beneficial.

## Información del artículo

- **Revista:** Stroke
- **Fecha de publicación:** 2026-03-01
- **Autores:** Vignan Yogendrakumar, Ronda Lun, Bruce C V Campbell, Aravind Ganesh
- **DOI:** [10.1161/STROKEAHA.125.053204](https://doi.org/10.1161/STROKEAHA.125.053204)
- **PubMed ID:** [41730038](https://pubmed.ncbi.nlm.nih.gov/41730038/)

## Referencias

Este artículo fue obtenido automáticamente desde [PubMed](https://pubmed.ncbi.nlm.nih.gov/41730038/), la base de datos de literatura biomédica del National Center for Biotechnology Information (NCBI).
